Publikationer i DiVA – Angelica Loskog
-
The signaling and the metabolic differences of various CAR T cell designs
Ingår i International Immunopharmacology, 2023.
DOI för The signaling and the metabolic differences of various CAR T cell designs
-
Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
Ingår i PLOS ONE, 2022.
DOI för Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis Ladda ner fulltext (pdf) av Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
-
Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
Ingår i MOLECULAR THERAPY-ONCOLYTICS, s. 429-442, 2022.
DOI för Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition Ladda ner fulltext (pdf) av Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
-
Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
Ingår i Cancer Imaging, 2022.
DOI för Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy Ladda ner fulltext (pdf) av Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
-
A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
Ingår i Scientific Reports, 2021.
DOI för A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer Ladda ner fulltext (pdf) av A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
-
Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up
Ingår i Frontiers in Veterinary Science, 2021.
DOI för Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up Ladda ner fulltext (pdf) av Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up
-
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
Ingår i Cancer Immunology and Immunotherapy, s. 2851-2865, 2021.
DOI för Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy Ladda ner fulltext (pdf) av Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
-
Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.
Ingår i Cancer Gene Therapy, s. 1188-1197, 2021.
DOI för Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.
-
Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes
Ingår i MOLECULAR THERAPY-ONCOLYTICS, s. 508-518, 2021.
DOI för Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes Ladda ner fulltext (pdf) av Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes
-
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
Ingår i Cancer Gene Therapy, s. 948-959, 2020.
DOI för Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40 Ladda ner fulltext (pdf) av Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
-
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Ingår i Scientific Reports, 2020.
DOI för Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway Ladda ner fulltext (pdf) av Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
-
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Ingår i Investigational new drugs, s. 1448-1453, 2020.
-
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Ingår i Frontiers in Immunology, 2020.
DOI för The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses Ladda ner fulltext (pdf) av The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
-
Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients
Ingår i BMC Cancer, 2019.
DOI för Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients Ladda ner fulltext (pdf) av Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients
-
Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients
Ingår i Scientific Reports, 2019.
DOI för Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients Ladda ner fulltext (pdf) av Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients
-
IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-beta, Collagen Type I, and PD-L1/PD-1
Ingår i Journal of Immunology, s. 787-798, 2019.
-
Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
Ingår i BMC Research Notes, 2019.
DOI för Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition Ladda ner fulltext (pdf) av Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
-
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Ingår i Clinical Cancer Research, s. 6185-6194, 2018.
-
An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
Ingår i European Journal of Haematology, s. 88-97, 2018.
DOI för An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome Ladda ner fulltext (pdf) av An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
-
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
Ingår i Frontiers in Immunology, 2018.
DOI för Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients Ladda ner fulltext (pdf) av Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
-
Activating CD40 While Inhibiting IL6R Induces Cytokine Production without PDL1 Upregulation in DCs
Ingår i Molecular Therapy, s. 54-54, 2017.
-
Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
Ingår i Gene Therapy, s. 92-103, 2017.
DOI för Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment Ladda ner fulltext (pdf) av Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
-
Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
Ingår i Journal of Translational Medicine, 2017.
DOI för Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients Ladda ner fulltext (pdf) av Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
-
Adenovirus-mediated CD40L gene transfer increases teffector/tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
Ingår i Scandinavian Journal of Immunology, s. 337-337, 2017.
-
An oncolytic virus targeting desmoplasia and immune activation in pancreatic cancer
Ingår i Scandinavian Journal of Immunology, s. 335-335, 2017.
-
Distinct phenotype of CD19-specific CAR T cells generated from healthy donor vs. patient lymphocytes using either IL-7/IL-15 or IL-2
Ingår i Oncology Research and Treatment, s. 213-213, 2017.
-
Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation
Ingår i American Journal of Transplantation, s. 472-472, 2017.
DOI för Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation
-
Immunological biomarkers correlate to survival in CAR19-treated patients
Ingår i Scandinavian Journal of Immunology, s. 337-337, 2017.
-
Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
Ingår i OncoTarget, s. 78573-78587, 2017.
DOI för Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients Ladda ner fulltext (pdf) av Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
-
Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion
Ingår i Cytotherapy, s. 689-702, 2017.
DOI för Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion Ladda ner fulltext (pdf) av Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion
-
Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer
Ingår i Neuroendocrinology, s. 54-66, 2017.
-
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.
Ingår i Clinical Cancer Research, s. 5846-5857, 2017.
-
The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation
Ingår i Immunopharmacology and immunotoxicology, s. 199-210, 2017.
-
A Clinical Trial Using Third Generation CD19 Targeting CAR T Cells for Relapsed Lymphoma and Leukemia
Ingår i Molecular Therapy, s. S295-S296, 2016.
-
A Novel Oncolytic Adenovirus Expressing Tumor Microenvironment Stimulators to Evoke and Facilitate Anti-Tumor Immune Responses
Ingår i Molecular Therapy, s. S206-S206, 2016.
-
An Oncolytic Adenovirus Gene Therapy Targeting Both Tumor Cell Survival and Desmoplasia in Pancreatic Cancer
Ingår i Molecular Therapy, s. S262-S262, 2016.
-
CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia: report from the Swedish phase Ulla trial
Ingår i CANCER IMMUNOLOGY RESEARCH, 2016.
-
Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer
Ingår i Journal of Translational Medicine, 2016.
DOI för Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer Ladda ner fulltext (pdf) av Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer
-
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli
Ingår i Leukemia research, s. 95-103, 2016.
-
Prognostic Implications Of An Active, Innate Or Anergic Immune Response In The Hodgkin Lymphoma Tumor Microenvironment
Ingår i Haematologica, s. 3-3, 2016.
-
T cell stimulation with different cytokines results in distinct phenotypes and cytotoxic activity of CD19-specific CART cells
Ingår i Oncology Research and Treatment, s. 136-136, 2016.
-
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
Ingår i Human Gene Therapy, s. 498-505, 2015.
DOI för CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
-
CD40L and 4-1BBL immunostimulating gene therapy reduces myeloid-derived suppressor cells (MDSCs) while promoting T and NK cell activation
Ingår i Human Gene Therapy, s. A53-A53, 2015.
-
CD40L/4-1BBL-expressing oncolytic adenovirus (LOAd703) stimulates human dendritic cell production of Th1 cytokines and antigen-specific T cells
Ingår i Human Gene Therapy, s. A58-A59, 2015.
-
Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity
Ingår i Gene Therapy, s. 596-601, 2015.
-
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
Ingår i Molecular Cancer Therapeutics, s. 1181-1191, 2015.
-
VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation
Ingår i The FASEB Journal, s. 227-238, 2015.
-
AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma
Ingår i Molecular Therapy, s. S247-S247, 2014.
-
Antigen Signaling Enhances Proliferation and Cytotoxic Capacity of CD19-Targeting CD28/4-1BB CAR T Cells During Expansion Without Inducing Exhaustion
Ingår i Molecular Therapy, s. S61-S61, 2014.
-
Assessing tissue damage in multiple sclerosis: a biomarker approach
Ingår i Acta Neurologica Scandinavica, s. 81-89, 2014.
DOI för Assessing tissue damage in multiple sclerosis: a biomarker approach
-
CAR T Cells Express CD40L and Activates Human Dendritic Cells
Ingår i Molecular Therapy, s. S61-S61, 2014.
-
Development of Gene Transfer Technology
Ingår i Human Gene Therapy, s. A3-A4, 2014.
-
Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand
Ingår i Cancer Immunology and Immunotherapy, s. 273-282, 2014.
-
Immunostimulating Gene Therapy Using an Oncolytic Adenovirus Armed with CD40 Ligand Potently Kill Tumor Cells, Activates Dendritic Cells and Induces T Cell Responses
Ingår i Molecular Therapy, s. S253-S254, 2014.
-
Intranasal Delivery of CNS-Retargeted Human Mesenchymal Stromal Cells Prolongs Treatment Efficacy of Experimental Autoimmune Encephalomyelitis
Ingår i Immunology, s. 431-441, 2014.
-
The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention
Ingår i Journal of Neuroimmunology, s. 153-159, 2014.
-
Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis
Ingår i Journal of Neuroimmunology, s. 141-141, 2014.
DOI för Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis
-
AdCD40L immunostimulatory gene therapy shifts the MDSC- and macrophage profiles and promotes T cell infiltration in the tumor microenvironment
Ingår i Human Gene Therapy, s. A169-A169, 2013.
-
Enhanced proliferation and tyrosine kinase pathway engagement in 4-1BB domain-containing CAR T cells
Ingår i Human Gene Therapy, s. A163-A163, 2013.
-
Genetically engineered T cells for the treatment of cancer
Ingår i Journal of Internal Medicine, s. 166-181, 2013.
DOI för Genetically engineered T cells for the treatment of cancer
-
Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
Ingår i PLOS ONE, s. e55818-, 2013.
DOI för Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia Ladda ner fulltext (pdf) av Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
-
Nya fotspår
Ingår i Skor är huvudsaken, s. 20-21, 2013.
-
Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma
Ingår i Journal of immunotherapy (1997), s. 350-358, 2013.
-
AdCD40L: Crossing the Valley of Death?
Ingår i International Reviews of Immunology, s. 289-298, 2012.
-
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
Ingår i Journal of Neuroinflammation, s. 112-, 2012.
DOI för CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery Ladda ner fulltext (pdf) av CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
-
T Regulatory Cells in B-Cell Malignancy: Tumor Support or Kiss of Death?
Ingår i Immunology, s. 255-260, 2012.
DOI för T Regulatory Cells in B-Cell Malignancy: Tumor Support or Kiss of Death?
-
AdCD40L Immunogene Therapy for Bladder Carcinoma: The First Phase I/IIa Trial
Ingår i Clinical Cancer Research, s. 3279-3287, 2010.
DOI för AdCD40L Immunogene Therapy for Bladder Carcinoma: The First Phase I/IIa Trial
-
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy
Ingår i Journal of immunotherapy (1997), s. 225-235, 2010.
DOI för Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy
-
Genetically Engineered Cells Target CNS and Cure Experimental Autoimmune Encephalomyelitis
Ingår i Human Gene Therapy, s. 1381-1381, 2010.
DOI för Genetically Engineered Cells Target CNS and Cure Experimental Autoimmune Encephalomyelitis
-
T regulatory cells lacking CD25 are increased in MS during relapse
Ingår i Autoimmunity, s. 590-597, 2010.
DOI för T regulatory cells lacking CD25 are increased in MS during relapse
-
Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition
Ingår i Journal of immunotherapy (1997), s. 785-792, 2009.
-
Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
Ingår i Acta Oncologica, s. 391-400, 2009.
DOI för Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue Ladda ner fulltext (pdf) av Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
-
The Janus faces of CD40 in cancer
Ingår i Seminars in Immunology, s. 301-307, 2009.
-
CD40L-based cancer therapy: Expert commentary
Ingår i New Gene Therapy and Cancer Research, 2008.
-
CpG oligonucleotides demonstrate increased therapeutic efficacy compared to BCG in an aggressive orthotopic bladder cancer model
Ingår i Journal of immunotherapy (1997), s. 34-42, 2008.
-
CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity
Ingår i Journal of immunotherapy (1997), s. 34-42, 2008.
-
Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma
Ingår i Journal of immunotherapy (1997), s. 377-384, 2008.
DOI för Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma
-
Genetic engineering for cancer immunotherapy
Ingår i Gene Therapy and Cancer Research Focus, 2008.